119 related articles for article (PubMed ID: 36038484)
1. Health-related Quality of Life of Patients Treated With Different Fractionation Schedules for Early Prostate Cancer Compared to the Age-standardized General Male Population.
Reinikainen P; Lehtonen M; Lehtinen I; Luukkaala T; Sintonen H; Kellokumpu-Lehtinen PL
Clin Genitourin Cancer; 2023 Feb; 21(1):146-154. PubMed ID: 36038484
[TBL] [Abstract][Full Text] [Related]
2. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
[TBL] [Abstract][Full Text] [Related]
3. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
4. A prospective analysis of health-related quality of life in intermediate and high-risk prostate cancer patients managed with intensity modulated radiation therapy, with vs. without hormonal therapy.
Caumont F; Conti G; Hurwitz LM; Kuo C; Levie KE; Badiozamani K; Frankel JK; Flores JP; Brand TC; Chaurasia A; Rosner IL; Stroup SP; Musser JE; Cullen J; Porter CR
Urol Oncol; 2020 Oct; 38(10):794.e1-794.e9. PubMed ID: 32139288
[TBL] [Abstract][Full Text] [Related]
5. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial.
Yeoh EE; Fraser RJ; McGowan RE; Botten RJ; Di Matteo AC; Roos DE; Penniment MG; Borg MF
Int J Radiat Oncol Biol Phys; 2003 Mar; 55(4):943-55. PubMed ID: 12605972
[TBL] [Abstract][Full Text] [Related]
6. A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy.
Lee WR; Hall MC; McQuellon RP; Case LD; McCullough DL
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):614-23. PubMed ID: 11597800
[TBL] [Abstract][Full Text] [Related]
7. Acute Side-effects of Different Radiotherapy Treatment Schedules in Early Prostate Cancer.
Reinikainen P; Kapanen M; Luukkaala T; Kellokumpu-Lehtinen PL
Anticancer Res; 2022 May; 42(5):2553-2565. PubMed ID: 35489724
[TBL] [Abstract][Full Text] [Related]
8. Quality-of-life outcomes in men treated for localized prostate cancer.
Litwin MS; Hays RD; Fink A; Ganz PA; Leake B; Leach GE; Brook RH
JAMA; 1995 Jan; 273(2):129-35. PubMed ID: 7799493
[TBL] [Abstract][Full Text] [Related]
9. The impact of chronic orofacial pain on health-related quality of life.
Forssell H; Sipilä K; Teerijoki-Oksa T; Vartiainen P; Kautiainen H; Sintonen H; Kalso E
Scand J Pain; 2020 Apr; 20(2):329-338. PubMed ID: 31881002
[TBL] [Abstract][Full Text] [Related]
10. Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life.
Kupelian PA; Reddy CA; Klein EA; Willoughby TR
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):988-93. PubMed ID: 11704322
[TBL] [Abstract][Full Text] [Related]
11. Higher sexual interest with androgen receptor inhibitor monotherapy than with castration plus an androgen receptor inhibitor in prostate cancer patients treated with curative radiotherapy, but otherwise small health-related quality of life differences: A randomised prospective 18-month follow-up study.
Majumder K; Nilsson S; Johansson H; Ullén A; Lennernäs B; Bergenmar M; Brandberg Y
Eur J Cancer; 2016 Sep; 65():43-51. PubMed ID: 27459586
[TBL] [Abstract][Full Text] [Related]
12. Moderately hypofractionated radiotherapy as definitive treatment for localized prostate cancer: Pattern of practice in German-speaking countries : A survey of the Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) and the Working Party on Radiation Oncology of the German Cancer Society (DKG-ARO).
Shelan M; Aebersold DM; Albrecht C; Böhmer D; Flentje M; Ganswindt U; Höcht S; Hölscher T; Müller AC; Niehoff P; Pinkawa M; Schmidt-Hegemann NS; Sedlmayer F; Wolf F; Zamboglou C; Zips D; Wiegel T; Ghadjar P
Strahlenther Onkol; 2021 Nov; 197(11):993-1000. PubMed ID: 34463814
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality-of-life changes due to high-dose-rate brachytherapy, low-dose-rate brachytherapy, or intensity-modulated radiation therapy for prostate cancer.
Strom TJ; Cruz AA; Figura NB; Shrinath K; Nethers K; Mellon EA; Fernandez DC; Saini AS; Hunt DC; Heysek RV; Wilder RB
Brachytherapy; 2015; 14(6):818-25. PubMed ID: 26452602
[TBL] [Abstract][Full Text] [Related]
14. Timing of Radiotherapy after Radical Prostatectomy: Effects on Health-Related Quality of Life.
Westhofen T; Buchner A; Schlenker B; Becker A; Li M; Belka C; Stief CG; Schmidt-Hegemann NS; Kretschmer A
J Urol; 2021 Nov; 206(5):1192-1203. PubMed ID: 34184923
[TBL] [Abstract][Full Text] [Related]
15. Trends in the 15D health-related quality of life over the first year following diagnosis of head and neck cancer.
Aro K; Bäck L; Loimu V; Saarilahti K; Rogers S; Sintonen H; Roine R; Mäkitie A
Eur Arch Otorhinolaryngol; 2016 Aug; 273(8):2141-50. PubMed ID: 26216625
[TBL] [Abstract][Full Text] [Related]
16. "Give me five" ultra-hypofractionated radiotherapy for localized prostate cancer: non-invasive ablative approach.
Marvaso G; Riva G; Ciardo D; Gandini S; Fodor C; Zerini D; Colangione SP; Timon G; Comi S; Cambria R; Cattani F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Med Oncol; 2018 May; 35(6):96. PubMed ID: 29748830
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life in long-term survivors with localised prostate cancer by therapy-Results from a population-based study.
Adam S; Koch-Gallenkamp L; Bertram H; Eberle A; Holleczek B; Pritzkuleit R; Waldeyer-Sauerland M; Waldmann A; Zeissig SR; Rohrmann S; Brenner H; Arndt V
Eur J Cancer Care (Engl); 2019 Sep; 28(5):e13076. PubMed ID: 31050091
[TBL] [Abstract][Full Text] [Related]
18. Analysis of health related quality of life (HRQoL) of patients with clinically localized prostate cancer, one year after treatment with external beam radiotherapy (EBRT) alone versus EBRT and high dose rate brachytherapy (HDRBT).
Joseph KJ; Alvi R; Skarsgard D; Tonita J; Pervez N; Small C; Tai P
Radiat Oncol; 2008 Jul; 3():20. PubMed ID: 18627617
[TBL] [Abstract][Full Text] [Related]
19. A prospective study of health-related quality-of-life outcomes for patients with low-risk prostate cancer managed by active surveillance or radiation therapy.
Banerji JS; Hurwitz LM; Cullen J; Wolff EM; Levie KE; Rosner IL; Brand TC; LʼEsperance JO; Sterbis JR; Porter CR
Urol Oncol; 2017 May; 35(5):234-242. PubMed ID: 28110975
[TBL] [Abstract][Full Text] [Related]
20. Patient-Reported Functional Outcomes After Hypofractionated or Conventionally Fractionated Radiation for Prostate Cancer: A National Cohort Study in England.
Nossiter J; Sujenthiran A; Cowling TE; Parry MG; Charman SC; Cathcart P; Clarke NW; Payne H; van der Meulen J; Aggarwal A
J Clin Oncol; 2020 Mar; 38(7):744-752. PubMed ID: 31895608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
